Bradykinin

PreclinicalSmall molecule

VVanderbilt University

Bradykinin is one of 59 small molecule programs targeting Angioedema. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AngioedemaActive, not recruiting

ObesityActive, not recruiting

Transplant RecipientWithdrawn

AngioedemaPreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Transplant RecipientPreclinical

Withdrawn

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Synthroid

IInstitut Jerome Lejeune

Phase 3

1 2

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Phase 3

1 3

NNC0487-0111

Novo Nordisk

Phase 3

11 4

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

4 5

Cagrisema

Novo Nordisk

Phase 3

5 6

Mibavademab

Regeneron

Phase 3

2 7

Elecoglipron

AstraZeneca

Phase 3

1 8

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Phase 3

2 9

Avapro

Sanofi

Preclinical

1 10

Amidate

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplant Recipient2 trials

Brachial Artery t-PA Release in Heart Transplant Recipients

Withdrawn·VVanderbilt University·N/A·NCT00780637

Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients

Withdrawn·VVanderbilt University·N/A·NCT00780377

Aspirin1 trial

Comparative Effects of Aspirin and NHP-544C

Completed·VVanderbilt University·N/A·NCT02189122·61 enrolled

Obesity1 trial

Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation

Terminated·VVanderbilt University·N/A·NCT00780481·13 enrolled

Angioedema1 trial

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled

Coronary Artery Disease1 trial

Tissue-Type Plasminogen Activator (t-PA) Release Predicts Major Adverse Cardiac Events (MACE) in Patients With Non-critical Coronary Artery Disease

Terminated·VVanderbilt University·Phase 1·NCT00868855·16 enrolled

2 more indications

Humans1 trial

Endothelial Hyperpolarization in Humans

Terminated·EEmory University·Phase 2·NCT00166166·174 enrolled

ARB1 trial

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated·VVanderbilt University Medical Center·Phase 4·NCT03738878·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Bradykinin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bradykinin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bradykinin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVanderbilt University

Bradykinin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplant Recipient2 trials

Aspirin1 trial

Obesity1 trial

Angioedema1 trial

Coronary Artery Disease1 trial

Humans1 trial

ARB1 trial

References

Drug Info

Quick Facts

Related News